Suppr超能文献

用5-氨基乙酰丙酸(ALA)诱导原卟啉IX(PPIX)对胃肠道肿瘤进行致敏和光动力疗法(PDT)。一项初步研究。

Sensitization and photodynamic therapy (PDT) of gastrointestinal tumors with 5-aminolaevulinic acid (ALA) induced protoporphyrin IX (PPIX). A pilot study.

作者信息

Mĺkvy P, Messmann H, Regula J, Conio M, Pauer M, Millson C E, MacRobert A J, Bown S G

机构信息

National Medical Laser Centre, University College London, Medical School, U.K.

出版信息

Neoplasma. 1995;42(3):109-13.

PMID:7637818
Abstract

5-Aminolaevulinic acid (ALA) is a promising agent for photodynamic therapy (PDT) sensitization as it can be given orally and only causes skin photosensitivity for 1-2 days. In fluorescence and photodynamic studies 26 patients with benign and malignant gastrointestinal tumors were given 30-60 mg ALA orally (single or divided doses) and biopsies were taken of tumor and normal tissue at 1-24 hours for fluorescence microscopy. With 30 mg/kg, highest protoporphyrin IX (PPIX) levels were seen in esophagus, duodenum and less in colon, but without tumor selectivity. Better tumor selectivity was seen in colon after 60 mg/kg (5:1). Six patients had transient rises in transaminases and five mild nausea. Sixteen patients were later treated (after further ALA) with red light (628 nm, bare or diffuser fibre, 50-100 J at 50 mW at each site). All but two showed subsequent necrosis, but only 0.5-1.5 mm of depth. PDT with ALA is simple, safe and promising for tumors in the gastrointestinal tract. Modification of treatment parameters may make it suitable for larger lesions.

摘要

5-氨基酮戊酸(ALA)是一种很有前景的光动力疗法(PDT)致敏剂,因为它可以口服,且只会导致1至2天的皮肤光敏性。在荧光和光动力研究中,26例患有良性和恶性胃肠道肿瘤的患者口服30至60毫克ALA(单次或分剂量),并在1至24小时内对肿瘤和正常组织进行活检,用于荧光显微镜检查。给予30毫克/千克时,食管和十二指肠中可见最高的原卟啉IX(PPIX)水平,结肠中的水平较低,但无肿瘤选择性。给予60毫克/千克后,结肠中可见更好的肿瘤选择性(5:1)。6例患者转氨酶短暂升高,5例有轻度恶心。16例患者后来(在进一步给予ALA后)接受了红光治疗(628纳米,裸光纤或漫射光纤,每个部位50毫瓦下50至100焦耳)。除2例患者外,所有患者随后均出现坏死,但深度仅为0.5至1.5毫米。ALA光动力疗法对于胃肠道肿瘤简单、安全且前景良好。治疗参数的调整可能使其适用于更大的病变。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验